Key facts
- Mabylon’s last known valuation is $33.5M (Jul 2021).
- It has raised $58.6M; the latest was Later Stage VC ($37.4M) in Aug 2025.
- Notable investors include Innosuisse, ALS Investment Fund, Target ALS, University of Zürich.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mabylon
- ·The full record, as it builds
Funding rounds
No funding rounds for Mabylon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mabylon
Operator of a biotechnology company intended to harness the therapeutic potential of naturally occurring human antibodies to treat allergies, inflammation, and neurodegenerative diseases. The company employs modern high-throughput technologies to screen the presence of therapeutically relevant antibodies within large human populations, enabling researchers to identify rare antibodies that are then used for therapeutic efficacy and clinical developability.
- Sector
- Healthcare
- HQ
- Schlieren, Switzerland
- Founded
- 2015
- Employees
- 24
- Website
- mabylon.com/
- Ownership
- Privately Held (backing)
Mabylon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mabylon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mabylon in its N-PORT filings yet. We sweep new filings monthly.